STOK
Stoke Therapeutics, Inc.
Biotechnology · Healthcare · United States
26.29
close · 2026-10-30
value
75
cheaper than peers75
quality
41
stronger fundamentals41
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | 2.6% | 89 |
| earnings yield, latest year | -0.5% | 77 |
| cash flow yield, 3 years ago | -2.1% | 76 |
| earnings yield, 1 year ago | -6.3% | 68 |
| cash flow yield, 1 year ago | -5.1% | 67 |
| earnings yield, 2 years ago | -9.1% | 66 |
| earnings yield, 3 years ago | -9.9% | 62 |
| cash flow yield, 2 years ago | -4.9% | 62 |
| price to book | 4.39× | 40 |
| price to sales | 61.49× | 20 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.8% | 94 |
| return on equity | -61.1% | 39 |
| operating margin | -701.7% | 27 |
| revenue growth | -32.5% | 25 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$106.2M |
| employees | 170 |
| first trade | 2019-06-19 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.12 | -1.65 | -2.38 | -2.60 |
| free cash flow | $44.9M | -$87.1M | -$82.7M | -$35.8M |
| net income | -$6.9M | -$89.0M | -$104.7M | -$101.1M |
| revenue | $184.4M | $36.6M | $8.8M | $12.4M |